Parity Pharma ApS: Financial statements 2025
CVR: 45346951
Source: annual report 2025, Danish Business Authority
20/01/2025 – 31/12/2025
Parity Pharma ApS (CVR 45346951) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 23,793 and a net result of DKK 18,491. Equity in the 2025 report amounted to DKK 58,491. The solvency ratio was 13.1%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 23,793
- Profit/Loss
- DKK 18,491
- Equity
- DKK 58,491
- Total Assets
- DKK 445,479
- Employees
- 1
Official annual report
How creditworthy is Parity Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of August 29, 2025, is registered as an owner of Parity Pharma ApS with an ownership share of 100%.
As of January 20, 2025, Simon James Dorris is registered as director of Parity Pharma ApS.
Parity Pharma ApS was founded on January 20, 2025.
About Parity Pharma ApS
Parity Pharma ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2025. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Asprita ApS. The management consists of Simon James Dorris. The company is owned by ASPRITA LIMITED. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of DKK 23,793 and a net result of DKK 18,491. Equity in the 2025 report amounted to DKK 58,491.